T. Sullivan

发表

Orally-Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 Diabetes: A Pilot Double-Blind, Randomized Clinical Trial

M. Hanefeld, T. Schall, Ernest Schell, 2012 .

Gene Expression Analysis of Host Innate Immune Responses during Lethal H5N1 Infection in Ferrets

Ali Danesh, Patricia V. Turner, Thomas Rowe, 2008, Journal of Virology.

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism

D. Birnbaum, J. Scoazec, T. Sullivan, 2009, British Journal of Cancer.

Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.

Feng Xu, T. Schall, Qingge Xu, 2007, Bioorganic & medicinal chemistry letters.

Discovery of potent and specific CXCR3 antagonists.

B. Lemon, S. Miao, T. Sullivan, 2012, Bioorganic & medicinal chemistry letters.

CXCR3 Antagonism Impairs the Development of Donor-Reactive, IFN-&ggr;-Producing Effectors and Prolongs Allograft Survival

R. Fairchild, T. Sullivan, J. Medina, 2009, Transplantation.

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

T. Schall, I. Charo, T. Sullivan, 2013, American journal of physiology. Renal physiology.

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

T. Schall, T. Sullivan, J. Jaén, 2013, Metabolism: clinical and experimental.

Type-2 Diabetes and Associated Comorbidities as an Inflammatory Syndrome

T. Sullivan, J. Jaén, J. Powers, 2012 .

CCR 2 antagonist CCX 140-B provides renal and glycemic benefits in diabetic transgenic human CCR 2 knockin mice

T. Schall, I. Charo, T. Sullivan, 2013 .

Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications.

T. Schall, I. Charo, Daniel M. Johnson, 2012, The Journal of pharmacology and experimental therapeutics.

Discovery and optimization of CRTH2 and DP dual antagonists.

T. Sullivan, G. Tonn, J. Medina, 2009, Bioorganic & medicinal chemistry letters.

CCR9 Antagonists in the Treatment of Ulcerative Colitis

James J. Campbell, T. Schall, T. Sullivan, 2015, Mediators of inflammation.

CCR 9 Antagonists in the Treatment of Ulcerative Colitis

James J. Campbell, T. Schall, T. Sullivan, 2015 .

Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.

Qingge Xu, W. Shen, T. Sullivan, 2011, ACS medicinal chemistry letters.

Design and optimization of imidazole derivatives as potent CXCR3 antagonists.

B. Lemon, S. Miao, T. Sullivan, 2008, Bioorganic & medicinal chemistry letters.

Optimization of a series of quinazolinone-derived antagonists of CXCR3.

T. Sullivan, G. Tonn, Andrew P. Marcus, 2009, Bioorganic & medicinal chemistry letters.

Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs

E. Kleinerman, J. Ricci, T. Sullivan, 2009, International journal of cancer.

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.

B. Lemon, T. Sullivan, G. Tonn, 2008, Bioorganic & medicinal chemistry letters.

CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens.

T. Schall, T. Sullivan, J. Jaén, 2013, Immunology letters.

CR 9 inhibition does not interfere with the development of immune tolerance to ral antigens

T. Schall, T. Sullivan, J. Powers, 2013 .

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.

T. Bush, Tzu-Hsuan Huang, D. Branstetter, 2014, Cancer cell.

Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab

T. Sullivan, Daqing Wang, L. Bhagat, 2014 .

Imidazo-pyrazine derivatives as potent CXCR3 antagonists.

B. Lemon, Zhulun Wang, S. Miao, 2009, Bioorganic & medicinal chemistry letters.